National Coverage Determination (NCD 90.2): Next Generation Sequencing (NGS) for Medicare Beneficiaries with Germline (Inherited) Cancer
This article, based on CR 11837, informs you about National Coverage Determination (NCD) 90.2, Next Generation Sequencing (NGS) for Medicare Beneficiaries with germline (inherited) cancer. Effective for dates of service on and after January 27, 2020, the Centers for Medicare & Medicaid Services (CMS) has determined that NGS, as a diagnostic laboratory test, is reasonable and necessary and covered nationally for patients with germline (inherited) cancer when performed in a CLIA-certified laboratory, when ordered by a treating physician, and when specific requirements are met.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: September 15, 2020
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.